• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非医疗机构环境下放射肿瘤学治疗的实施在全国的差异。

National variation in the delivery of radiation oncology procedures in the non-facility-based setting.

机构信息

Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA, USA.

出版信息

Cancer Med. 2021 Jul;10(14):4734-4742. doi: 10.1002/cam4.4028. Epub 2021 Jun 2.

DOI:10.1002/cam4.4028
PMID:34076341
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8290244/
Abstract

PURPOSE

Though utilization of medical procedures has been shown to vary considerably across the United States, similar efforts to characterize variation in the delivery of radiation therapy (RT) procedures have not been forthcoming. Our aim was to characterize variation in the delivery of common RT procedures in the Medicare population. We hypothesized that delivery would vary significantly based on provider characteristics.

METHODS

The Centers for Medicare and Medicaid Services (CMS) Physician and Other Supplier Public Use File was linked to the CMS Physician Compare (PC) database by physician NPI to identify and sum all treatment delivery charges submitted by individual radiation oncologists in the non-facility-based (NFB) setting in 2016. Multivariable logistic regression analysis was carried out to determine provider characteristics (gender, practice rurality, practice region, and years since graduation) that predicted for the delivery of 3D conformal RT (3DCRT), intensity modulated RT (IMRT), stereotactic body RT (SBRT), stereotactic radiosurgery (SRS), low dose rate (LDR) brachytherapy, and high dose rate (HDR) brachytherapy delivery in the Medicare patient population. The overall significance of categorical variables in the multivariable logistic regression model was assessed by the likelihood ratio test (LRT).

RESULTS

In total, 1,802 physicians from the NFB practice setting were analyzed. Male gender predicted for greater LDR brachytherapy delivery (OR 8.19, 95% CI 2.58-26.05, p < 0.001), but not greater delivery of other technologies. Metropolitan practice was the only predictor for greater HDR brachytherapy utilization (OR 12.95, 95% CI 1.81-92.60, p = 0.01). Practice region was predictive of the delivery of 3DCRT, SRS and SBRT (p < 0.01, p < 0.001, and p < 0.001, respectively). With the Northeast as the reference region, 3DCRT was more likely to be delivered by providers in the South (OR 1.33, 95% CI 1.09-1.62, p < 0.01) and the West (OR 1.38, 95% CI 1.11-1.71, p < 0.01). At the same time, SRS use was less likely in the Midwest (OR 0.71, 95% CI 0.55-0.91, p < 0.01), South (OR 0.49, 95% CI 0.40-0.61, p < 0.001), and West (OR 0.43, 95% CI 0.34-0.55, p < 0.001). SBRT, on the other hand, was more commonly utilized in the Midwest (OR 2.63, 95% CI 1.13-6.13, p = 0.03), South (OR 3.44, 95% CI 1.58-7.49, p < 0.01), and West (OR 4.87, 95% CI 2.21-10.72, p < 0.001). HDR brachytherapy use was also more likely in the Midwest (OR 1.97, 95% CI 1.11-3.49, p = 0.02) and West (OR 1.87, 95% CI 1.08-3.24, p = 0.03). While the degree held by the billing physician did not predict for delivery of a given procedure, greater years since graduation was related to decreased likelihood of SBRT use (OR 0.98, 95% CI 0.96-0.99, p < 0.001) and increased likelihood of LDR brachytherapy use (OR 1.02, 95% CI 1.00-1.04, p = 0.02).

CONCLUSIONS

Substantial geographic variation in the use of specific RT technologies was identified. The degree to which this variation reflects effective care, preference-sensitive care, or supply-sensitive care warrants further investigation.

摘要

目的

尽管已经证实美国各地的医疗程序利用情况存在很大差异,但尚未有类似的努力来描述放射治疗(RT)程序的提供情况。我们的目的是描述医疗保险人群中常见 RT 程序的提供情况。我们假设提供情况会根据提供者的特征而有很大差异。

方法

将医疗保险和医疗补助服务中心(CMS)医生和其他供应商公共使用文件与 CMS 医生比较(PC)数据库通过医生 NPI 链接,以识别和汇总 2016 年非设施基础(NFB)环境中每位放射肿瘤学家提交的所有治疗交付费用。进行多变量逻辑回归分析,以确定预测 Medicare 患者人群中 3D 适形 RT(3DCRT)、强度调制 RT(IMRT)、立体定向体 RT(SBRT)、立体定向放射外科(SRS)、低剂量率(LDR)近距离放射治疗和高剂量率(HDR)近距离放射治疗的提供者特征(性别、实践农村性、实践地区和毕业后年限)。通过似然比检验(LRT)评估多变量逻辑回归模型中分类变量的整体显著性。

结果

总共分析了来自 NFB 实践环境的 1802 名医生。男性性别预测 LDR 近距离放射治疗的使用更高(OR 8.19,95%CI 2.58-26.05,p<0.001),但其他技术的使用则没有增加。大都市实践是唯一预测 HDR 近距离放射治疗利用率更高的因素(OR 12.95,95%CI 1.81-92.60,p=0.01)。实践地区预测了 3DCRT、SRS 和 SBRT 的使用(p<0.01,p<0.001 和 p<0.001,分别)。以东北部为参考区域,3DCRT 更可能由南部(OR 1.33,95%CI 1.09-1.62,p<0.01)和西部(OR 1.38,95%CI 1.11-1.71,p<0.01)的提供者提供。与此同时,在中西部(OR 0.71,95%CI 0.55-0.91,p<0.01)、南部(OR 0.49,95%CI 0.40-0.61,p<0.001)和西部(OR 0.43,95%CI 0.34-0.55,p<0.001),SRS 的使用则更少。另一方面,SBRT 在中西部(OR 2.63,95%CI 1.13-6.13,p=0.03)、南部(OR 3.44,95%CI 1.58-7.49,p<0.01)和西部(OR 4.87,95%CI 2.21-10.72,p<0.001)中更常见。HDR 近距离放射治疗的使用在中西部(OR 1.97,95%CI 1.11-3.49,p=0.02)和西部(OR 1.87,95%CI 1.08-3.24,p=0.03)也更高。虽然计费医生的学位水平没有预测特定程序的使用,但毕业后年限的增加与 SBRT 使用的可能性降低(OR 0.98,95%CI 0.96-0.99,p<0.001)和 LDR 近距离放射治疗使用的可能性增加(OR 1.02,95%CI 1.00-1.04,p=0.02)有关。

结论

确定了特定 RT 技术使用的大量地理差异。这种差异在多大程度上反映了有效护理、偏好敏感护理还是供应敏感护理,需要进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba2a/8290244/29236b21d2a0/CAM4-10-4734-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba2a/8290244/29236b21d2a0/CAM4-10-4734-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba2a/8290244/29236b21d2a0/CAM4-10-4734-g002.jpg

相似文献

1
National variation in the delivery of radiation oncology procedures in the non-facility-based setting.非医疗机构环境下放射肿瘤学治疗的实施在全国的差异。
Cancer Med. 2021 Jul;10(14):4734-4742. doi: 10.1002/cam4.4028. Epub 2021 Jun 2.
2
Provider-Level Variation in Treatment Planning of Radiation Oncology Procedures in the United States.美国放射肿瘤治疗计划中的医疗机构层面差异
JCO Oncol Pract. 2021 Dec;17(12):e1905-e1912. doi: 10.1200/OP.20.00441. Epub 2021 Jan 8.
3
Provider variability in intensity modulated radiation therapy utilization among Medicare beneficiaries in the United States.美国医疗保险受益人群中调强放射治疗利用的提供者差异。
Pract Radiat Oncol. 2018 Sep-Oct;8(5):e329-e336. doi: 10.1016/j.prro.2018.02.004. Epub 2018 Feb 16.
4
Assessment of Differences in Clinical Activity and Medicare Payments Among Female and Male Radiation Oncologists.评估女性和男性放射肿瘤学家在临床活动和医疗保险支付方面的差异。
JAMA Netw Open. 2019 Mar 1;2(3):e190932. doi: 10.1001/jamanetworkopen.2019.0932.
5
Influence of Geography on Prostate Cancer Treatment.地理因素对前列腺癌治疗的影响。
Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1286-1295. doi: 10.1016/j.ijrobp.2020.11.055. Epub 2020 Dec 13.
6
Variations in Medicare Reimbursement in Radiation Oncology: An Analysis of the Medicare Provider Utilization and Payment Data Set.医疗保险在放射肿瘤学中的报销差异:对医疗保险提供者利用和支付数据集的分析。
Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1000-5. doi: 10.1016/j.ijrobp.2015.11.045. Epub 2015 Dec 18.
7
Opioid prescription patterns among radiation oncologists in the United States.美国放射肿瘤学家的阿片类药物处方模式。
Cancer Med. 2020 May;9(10):3297-3304. doi: 10.1002/cam4.2907. Epub 2020 Mar 13.
8
[Status report of Hungarian radiotherapy based on treatment data, available infrastucture, and human resources].[基于治疗数据、现有基础设施和人力资源的匈牙利放射治疗现状报告]
Magy Onkol. 2015 Jun;59(2):85-94. Epub 2015 Mar 18.
9
Time-driven activity-based cost comparison of prostate cancer brachytherapy and intensity-modulated radiation therapy.前列腺癌近距离放射治疗与调强放射治疗的时间驱动基于活动的成本比较
Brachytherapy. 2018 May-Jun;17(3):556-563. doi: 10.1016/j.brachy.2018.01.013. Epub 2018 Mar 5.
10
The Impact of Radiation Oncologists on the Early Adoption of Hypofractionated Radiation Therapy for Early-Stage Breast Cancer.放疗肿瘤学家对早期采用适形分割放疗治疗早期乳腺癌的影响。
Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):571-580. doi: 10.1016/j.ijrobp.2016.11.009. Epub 2016 Nov 15.

引用本文的文献

1
Radiation Oncology Virtual Education Rotation (ROVER) 2.0 for Residents: Implementation and Outcomes.放射肿瘤学虚拟教育轮转(ROVER)2.0 课程在住院医师中的实施与结果。
J Cancer Educ. 2023 Jun;38(3):977-984. doi: 10.1007/s13187-022-02216-1. Epub 2022 Sep 9.

本文引用的文献

1
Provider-Level Variation in Treatment Planning of Radiation Oncology Procedures in the United States.美国放射肿瘤治疗计划中的医疗机构层面差异
JCO Oncol Pract. 2021 Dec;17(12):e1905-e1912. doi: 10.1200/OP.20.00441. Epub 2021 Jan 8.
2
THE PRICE AIN'T RIGHT? HOSPITAL PRICES AND HEALTH SPENDING ON THE PRIVATELY INSURED.价格不合理?医院价格与私人保险人群的医疗支出
Q J Econ. 2019 Feb;134(1):51-107. doi: 10.1093/qje/qjy020. Epub 2018 Sep 4.
3
Trends in the Use of Stereotactic Body Radiotherapy for Treatment of Prostate Cancer in the United States.
美国立体定向体部放射治疗前列腺癌的应用趋势。
JAMA Netw Open. 2020 Feb 5;3(2):e1920471. doi: 10.1001/jamanetworkopen.2019.20471.
4
A Phase II Trial of Stereotactic Ablative Radiation Therapy as a Boost for Locally Advanced Cervical Cancer.立体定向消融放疗作为局部晚期宫颈癌增敏的 II 期临床试验。
Int J Radiat Oncol Biol Phys. 2020 Mar 1;106(3):464-471. doi: 10.1016/j.ijrobp.2019.10.042. Epub 2019 Nov 5.
5
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.超分割与常规分割放疗治疗前列腺癌的比较:HYPO-RT-PC 随机、非劣效、III 期临床试验的 5 年结果。
Lancet. 2019 Aug 3;394(10196):385-395. doi: 10.1016/S0140-6736(19)31131-6. Epub 2019 Jun 18.
6
SABR-COMET: harbinger of a new cancer treatment paradigm.立体定向消融放疗-多中心随机对照试验:一种新癌症治疗模式的先驱
Lancet. 2019 May 18;393(10185):2013-2014. doi: 10.1016/S0140-6736(19)30278-8. Epub 2019 Apr 11.
7
Closing the Gender Wage Gap and Achieving Professional Equity in Medicine.消除性别工资差距并实现医学领域的职业公平。
JAMA. 2019 May 7;321(17):1665-1666. doi: 10.1001/jama.2019.4168.
8
Assessment of Differences in Clinical Activity and Medicare Payments Among Female and Male Radiation Oncologists.评估女性和男性放射肿瘤学家在临床活动和医疗保险支付方面的差异。
JAMA Netw Open. 2019 Mar 1;2(3):e190932. doi: 10.1001/jamanetworkopen.2019.0932.
9
Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer.立体定向体部放疗治疗低危和中危前列腺癌的长期疗效。
JAMA Netw Open. 2019 Feb 1;2(2):e188006. doi: 10.1001/jamanetworkopen.2018.8006.
10
Evaluating the urban-rural paradox: The complicated relationship between distance and the receipt of guideline-concordant care among cervical cancer patients.评估城乡悖论:距离与宫颈癌患者接受规范治疗之间的复杂关系。
Gynecol Oncol. 2019 Jan;152(1):112-118. doi: 10.1016/j.ygyno.2018.11.010. Epub 2018 Nov 12.